<DOC>
	<DOCNO>NCT00897715</DOCNO>
	<brief_summary>There exponential growth number people Chronic Kidney Disease ( CKD ) need dialysis transplantation , increase 209,000 1991 472,000 2004 . This highly concern due human cost burden represent health care system . Recent comparison NHANES survey show CKD prevalence increase 10 % 1988-1994 13 % 1999-2004 . Patients CKD likely die premature cardiovascular death reach ESRD . In reach ESRD , cardiovascular disease ( CVD ) account half deaths dialysis . The prevalence CKD VA population 20 % , 31.6 % diabetic , high general population . These observation emphasize need risk stratification , early detection , prevention effort respect CKD progression CVD burden afflict CKD target intervention high-risk group ( personalized medicine ) . CKD multifactorial , however familial aggregation end-stage renal disease ( ESRD ) CKD report type nephropathy underscore `` kidney disease genetic susceptibility `` . Genetic predisposition ESRD strong African Africans . African Americans first-degree relative ESRD 9-fold increase risk ESRD vs. 3-5 fold increase white . Studies consistently show CKD inflammatory process biomarkers inflammation increase since early stage CKD . CVD also inflammatory process , gene affect inflammation associate high risk CVD . Since inflammation common denominator disease process ( CKD CVD ) , likely gene govern inflammation may involve , predisposition CKD burden CVD attributable CKD . Additionally inflammation play central role burden CVD CKD drug modulate inflammation impact : CKD progression non-traditional CV risk factor CVD . The overall goal proposal study genetic predisposition CKD , CVD risk CKD inflammatory pathway , effect potent anti-inflammatory intervention like interleukin 1 receptor antagonist ( IL-1ra ) , inflame patient CKD stag 3 &amp; 4 . Specific Aims : 1 ) To determine specific polymorphism/haplotypes , genotype combination gene-environmental interaction affect inflammation , available Third National Health Nutrition Examination Survey ( DNA data set ) , specifically CRP , IL-1 , IL-10 TNF- gene , associate CKD . 2 ) To determine specific polymorphism haplotype study Aim 1 associate faster CKD progression CV outcomes longitudinal cohort African American Study Kidney Disease . 3 ) To determine target anti-inflammatory intervention , IL-1 receptor antagonist , modulate systemic inflammation , endothelial function , oxidative stress urinary cytokine , propose surrogate marker CVD CKD progression inflame patient CKD stag 3 &amp; 4 .</brief_summary>
	<brief_title>Inflammation Chronic Kidney Disease Cardiovascular Disease - The Role Genetics Interleukin-1 Receptor Antagonist ( IL-1ra )</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>18 year age old ; estimate glomerular filtration rate ( eGFR ) 1560 mL/min/1.73m2 ; Must stable regimen medication affect inflammatory axis ( Aspirin , Thiazolidinediones , statins ) ; Willing able comply clinic visit studyrelated procedure ; Provide sign informed consent . Recent infection hospitalization ( within one month ) ; History active chronic hepatitis B , history active chronic hepatitis C , human immunodeficiency virus ( HIV ) , history tuberculosis ( patient must purify protein derivate negative ) ; Patients take tumor necrosis factor ( TNF ) inhibitor , TNF blocker , interleukin6 ( IL6 ) blocker interleukin1 ( IL1 ) block drug ; Patients steroid receive immunosuppressive agent antiinflammatory drug ( aspirin 325 mg day allow ) one month prior ; Have clinically significant chronic lymphopenia ( low white blood cell count ) ; History malignancy prior 5 year . Any history melanoma lymphoma ; Life expectancy less six month ; Intolerance study medication ; The use investigational drug 30 day prior enrollment within five halflives medication use ; Live vaccination within 3 month prior start trial , trial , 3 month follow last dose ; Currently receive parenteral iron schedule receive parenteral iron study ; Uncontrolled diabetes mellitus ( glycated hemoglobin &gt; 10 ) ; high sensitivity creactive protein ( hsCRP ) &lt; 2mg/L &gt; 30 mg/L ; Body mass index ( BMI ) &gt; 40 ; Known diagnosis severe congestive heart failure document ejection fraction ( EF ) &lt; 35 % ; Pregnant breastfeed woman ; Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device ( IUD ) ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) . Contraception require men document vasectomy . **Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CKD</keyword>
	<keyword>inflammation</keyword>
	<keyword>CVD</keyword>
</DOC>